WallStSmart

McCormick & Company Incorporated (MKC-V)vsPrenetics Global Ltd (PRE)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

McCormick & Company Incorporated generates 4872% more annual revenue ($7.69B vs $154.59M). MKC-V leads profitability with a 19.4% profit margin vs -30.4%. MKC-V earns a higher WallStSmart Score of 59/100 (C).

MKC-V

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.5Value: 8.0Quality: 5.0
Piotroski: 4/9Altman Z: 1.58

PRE

Avoid

35

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MKC-VUndervalued (+77.9%)

Margin of Safety

+77.9%

Fair Value

$325.30

Current Price

$48.91

$276.39 discount

UndervaluedFair: $325.30Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MKC-V4 strengths · Avg: 8.8/10
P/E RatioValuation
8.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

PRE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
210.7%10/10

Revenue surging 210.7% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

MKC-V3 concerns · Avg: 3.3/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

EPS GrowthGrowth
-57.1%2/10

Earnings declined 57.1%

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$338.57M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-72.7%2/10

ROE of -72.7% — below average capital efficiency

Free Cash FlowQuality
$-30.91M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MKC-V

The strongest argument for MKC-V centers on P/E Ratio, Return on Equity, Price/Book. Profitability is solid with margins at 19.4% and operating margin at 17.8%. Revenue growth of 17.4% demonstrates continued momentum.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity. Revenue growth of 210.7% demonstrates continued momentum.

Bear Case : MKC-V

The primary concerns for MKC-V are PEG Ratio, Altman Z-Score, EPS Growth.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MKC-V profiles as a growth stock while PRE is a hypergrowth play — different risk/reward profiles.

MKC-V carries more volatility with a beta of 0.64 — expect wider price swings.

PRE is growing revenue faster at 210.7% — sustainability is the question.

MKC-V generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

MKC-V scores higher overall (59/100 vs 35/100), backed by strong 19.4% margins and 17.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

McCormick & Company Incorporated

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

McCormick & Company is an American multinational food company that manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavoring products to retail outlets, food manufacturers, and foodservice businesses.

Prenetics Global Ltd

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Prenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment opportunity within the dynamic healthcare sector.

Want to dig deeper into these stocks?